N Starling1, F Vázquez-Mazón2, D Cunningham3, I Chau1, J Tabernero4, F J Ramos4, T J Iveson5, M P Saunders6, E Aranda7, A M Countouriotis8, A Ruiz-Garcia9, G Wei10, J M Tursi11, C Guillen-Ponce12, A Carrato12. 1. Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK. 2. Medical Oncology Department, Elche University Hospital, Elche. 3. Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK. Electronic address: david.cunningham@rmh.nhs.uk. 4. Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Department of Medical Oncology, Southampton Oncology Centre, Southampton General Hospital, Southampton. 6. Department of Radiotherapy and Clinical Oncology, Christie Hospital, Manchester, UK. 7. Department of Medical Oncology, Hospital Universitario Reina Sofia, Cordoba, Spain. 8. Pfizer Oncology, Clinical Development. 9. Pfizer Oncology, Clinical Pharmacology. 10. Pfizer Oncology, Oncology Statistics, La Jolla, USA. 11. Pfizer Italia Srl, Clinical Development Oncology, Milan, Italy. 12. Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Abstract
BACKGROUND: This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In this multicentre, phase I, open-label, dose-finding trial, FOLFIRI was administered every 2 weeks. Two sunitinib regimens were explored: Schedule 4/2 (4 weeks on, 2 weeks off; 37.5 and 50 mg/day) and continuous daily dosing (CDD; 37.5 and 25 mg/day). Dose-limiting toxic toxicities (DLTs) were evaluated during weeks 1-6. Efficacy was a secondary objective. RESULTS: Thirty-seven patients were enrolled. The 37.5 mg/day Schedule 4/2 cohort had zero of six DLTs, was expanded by 15 patients and declared the MTD. The MTD was exceeded at all other sunitinib doses and schedules; DLTs included febrile neutropenia (n=1), grade 4 neutropenia (n=4) and grade 3 deep vein thrombosis with grade 4 neutropenia (n=1). At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7). CONCLUSIONS: The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2. CDD of sunitinib at 37.5 or 25 mg/day plus FOLFIRI was not feasible.
BACKGROUND: This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In this multicentre, phase I, open-label, dose-finding trial, FOLFIRI was administered every 2 weeks. Two sunitinib regimens were explored: Schedule 4/2 (4 weeks on, 2 weeks off; 37.5 and 50 mg/day) and continuous daily dosing (CDD; 37.5 and 25 mg/day). Dose-limiting toxic toxicities (DLTs) were evaluated during weeks 1-6. Efficacy was a secondary objective. RESULTS: Thirty-seven patients were enrolled. The 37.5 mg/day Schedule 4/2 cohort had zero of six DLTs, was expanded by 15 patients and declared the MTD. The MTD was exceeded at all other sunitinib doses and schedules; DLTs included febrile neutropenia (n=1), grade 4 neutropenia (n=4) and grade 3 deep vein thrombosis with grade 4 neutropenia (n=1). At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7). CONCLUSIONS: The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2. CDD of sunitinib at 37.5 or 25 mg/day plus FOLFIRI was not feasible.
Authors: Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2015-05 Impact factor: 4.335
Authors: Markus Moehler; Irina Gepfner-Tuma; Annett Maderer; Peter C Thuss-Patience; Joern Ruessel; Susanna Hegewisch-Becker; Hansjochen Wilke; Salah-Eddin Al-Batran; Mohammad-Reza Rafiyan; Florian Weißinger; Hans-Joachim Schmoll; Frank Kullmann; Ludwig Fischer von Weikersthal; Jens T Siveke; Jens Weusmann; Stephan Kanzler; Carl Christoph Schimanski; Melanie Otte; Lukas Schollenberger; Jochem Koenig; Peter R Galle Journal: BMC Cancer Date: 2016-08-31 Impact factor: 4.430
Authors: B Schultheis; G Folprecht; J Kuhlmann; R Ehrenberg; U T Hacker; C H Köhne; M Kornacker; O Boix; J Lettieri; J Krauss; R Fischer; S Hamann; D Strumberg; K B Mross Journal: Ann Oncol Date: 2013-03-13 Impact factor: 32.976
Authors: Letizia Procaccio; Vera Damuzzo; Francesca Di Sarra; Alberto Russi; Federica Todino; Vincenzo Dadduzio; Francesca Bergamo; Alessandra Anna Prete; Sara Lonardi; Hans Prenen; Angelo Claudio Palozzo; Fotios Loupakis Journal: Drug Saf Date: 2019-02 Impact factor: 5.228